207 related articles for article (PubMed ID: 24192532)
21. Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
Tricker AR
Toxicology; 2003 Feb; 183(1-3):151-73. PubMed ID: 12504349
[TBL] [Abstract][Full Text] [Related]
22. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.
Erickson-Ridout KK; Zhu J; Lazarus P
Pharmacogenet Genomics; 2011 Sep; 21(9):539-51. PubMed ID: 21750471
[TBL] [Abstract][Full Text] [Related]
23. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
24. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
25. Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6.
Bloom AJ; Harari O; Martinez M; Madden PA; Martin NG; Montgomery GW; Rice JP; Murphy SE; Bierut LJ; Goate A
Hum Mol Genet; 2012 Jul; 21(13):3050-62. PubMed ID: 22451501
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495
[TBL] [Abstract][Full Text] [Related]
27. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent.
Mwenifumbo JC; Al Koudsi N; Ho MK; Zhou Q; Hoffmann EB; Sellers EM; Tyndale RF
Hum Mutat; 2008 May; 29(5):679-88. PubMed ID: 18360915
[TBL] [Abstract][Full Text] [Related]
28. Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance.
Liakoni E; Tyndale RF; Jacob P; Dempsey DA; Addo N; Benowitz NL
Pharmacogenet Genomics; 2021 Jul; 31(5):97-107. PubMed ID: 33675323
[TBL] [Abstract][Full Text] [Related]
29. Genetic influences on individual differences in nicotine glucuronidation.
Lessov-Schlaggar CN; Benowitz NL; Jacob P; Swan GE
Twin Res Hum Genet; 2009 Oct; 12(5):507-13. PubMed ID: 19803778
[TBL] [Abstract][Full Text] [Related]
30. Ethnic differences in nicotine metabolic rate among New Zealanders.
Lea R; Benowitz N; Green M; Fowles J; Vishvanath A; Dickson S; Lea M; Woodward A; Chambers G; Phillips D
N Z Med J; 2005 Dec; 118(1227):U1773. PubMed ID: 16372023
[TBL] [Abstract][Full Text] [Related]
31. Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies.
Giratallah HK; Chenoweth MJ; Addo N; Ahluwalia JS; Cox LS; Lerman C; George TP; Benowitz NL; Tyndale RF
Drug Alcohol Depend; 2021 Jun; 223():108708. PubMed ID: 33873029
[TBL] [Abstract][Full Text] [Related]
32. Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo.
Piliguian M; Zhu AZ; Zhou Q; Benowitz NL; Ahluwalia JS; Sanderson Cox L; Tyndale RF
Pharmacogenet Genomics; 2014 Feb; 24(2):118-28. PubMed ID: 24305170
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal Influence of Pregnancy on Nicotine Metabolic Pathways.
Taghavi T; Arger CA; Heil SH; Higgins ST; Tyndale RF
J Pharmacol Exp Ther; 2018 Feb; 364(2):238-245. PubMed ID: 29158210
[TBL] [Abstract][Full Text] [Related]
34. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.
Zhu AZ; Renner CC; Hatsukami DK; Swan GE; Lerman C; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):708-18. PubMed ID: 23371292
[TBL] [Abstract][Full Text] [Related]
35. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people.
Binnington MJ; Zhu AZ; Renner CC; Lanier AP; Hatsukami DK; Benowitz NL; Tyndale RF
Pharmacogenet Genomics; 2012 Jun; 22(6):429-40. PubMed ID: 22569203
[TBL] [Abstract][Full Text] [Related]
36. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
37. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
38. A novel duplication type of CYP2A6 gene in African-American population.
Fukami T; Nakajima M; Yamanaka H; Fukushima Y; McLeod HL; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):515-20. PubMed ID: 17267622
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
Mwenifumbo JC; Lessov-Schlaggar CN; Zhou Q; Krasnow RE; Swan GE; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2008 Jan; 83(1):115-21. PubMed ID: 17522595
[TBL] [Abstract][Full Text] [Related]
40. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.
Zhang X; Ameno K; Ameno S; Kinoshita H; Kubota T; Kumihashi M; Mostofa J; Iwahashi K; Ijiri I
Drug Chem Toxicol; 2002 May; 25(2):203-13. PubMed ID: 12024803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
